PET studies in Parkinson's disease motor and cognitive dysfunction

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Pavese, Nicola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bradykinesia; Dementia; Neuroimaging; Parkinson; PET; Tremor

Indexed keywords

6 FLUORODOPA F 18; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CARBON 11; CHOLINESTERASE INHIBITOR; DIHYDROTETRABENAZINE; DONEPEZIL; DOPAMINE TRANSPORTER; FLORBETABEN; FLUORODEOXYGLUCOSE F 18; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RACLOPRIDE;

ARTICLE; BRADYKINESIA; BRAIN METABOLISM; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG UPTAKE; DYSKINESIA; HUMAN; IN VIVO STUDY; ISOTOPE TRACING; MONOAMINERGIC SYSTEM; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREMOR;

EID: 84858627833     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70031-1     Document Type: Article

References (20)

1. Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999;166:141-51.
2. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
3. Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 2007;254:185-90.
4. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab 1994;14:783-801.
5. Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, Ma Y, et al. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 2011;54:1244-53.
6. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ; 11C-WAY 100635 PET study. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003;60:601-5.
7. Bohnen NI, Müller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009;73:1670-6.
8. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006;67(9):1612-7.
9. Jokinen P, Brück A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009;15: 88-93.
10. Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008;163:171-82.
11. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marié RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236-45.
12. Ito K, Nagano-Saito A, Kato T, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002;125:1358-65.
13. Jokinen P, Scheinin N, Aalto S, Någren K, Savisto N, Parkkola R, et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010;16:666-70.
14. Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52:848-55.
15. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14:1357-62.
16. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-22.
17. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253:242-7.
18. Lee PH, Yong SW, An YS. Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy. J Nucl Med 2008;49:2006-11.
19. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-8.
20. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011;52:1210-7.